# Tambiciclib PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tambiciclib

> Tambiciclib, sponsored by SELLAS Life Sciences Group, Inc. (SLS): 7 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | tambiciclib |
| Codes | SLS009, GFH009 |
| Sponsor | SELLAS Life Sciences Group, Inc. (SLS) https://sec-api.dev/companies/sls/catalysts |
| Indications | [acute myeloid leukemia](https://sec-api.dev/indications/acute-myeloid-leukemia) |
| Modality | small_molecule |
| FDA designations | fast track, orphan |

## Timeline

### Mar 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2025-10-27.
- SEC prospectus (424B) (accession 0001104659-25-102602): "In March 2024, we announced positive topline data from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r/ AML." https://www.sec.gov/Archives/edgar/data/1390478/000110465925102602/tm2529505d2_424b5.htm
- SEC Form 10-K (accession 0001390478-25-000003): "In March 2024, we announced positive topline data from the Phase 2a study of SLS009 in combination with aza/ven in r/r AML." https://www.sec.gov/Archives/edgar/data/1390478/000139047825000003/sls-20241231.htm
- SEC prospectus (424B) (accession 0001104659-25-007097): "In March 2024, we announced positive topline data from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r/ AML." https://www.sec.gov/Archives/edgar/data/1390478/000110465925007097/tm254790d2_424b5.htm
- SEC Form 10-Q (accession 0001390478-24-000021): "In March 2024, we announced positive topline data from the Phase 2a clinical trial of SLS009 in combination with aza/ven in r/r/ AML." https://www.sec.gov/Archives/edgar/data/1390478/000139047824000021/sls-20240930.htm

### Q4 2024: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Acute Myeloid Leukemia.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001390478-24-000022): "Based on a detailed analysis of all unblinded data, the IDMC projected that the interim analysis (60 events) will occur in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-24-000022): "Initial safety and efficacy data are expected to be reported in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-24-000022): "- Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 -" https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm

### Q4 2024: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0001390478-24-000022): "Additional topline data updates are expected in the fourth quarter of 2024." https://www.sec.gov/Archives/edgar/data/1390478/000139047824000022/sls-202411138xkexhibit991.htm

### 2025: interim data readout

- Status: scheduled. Date confidence: year. Stage: 3.
- First seen 2025-03-20, last confirmed 2025-03-20.
- Press release filed with the SEC (EX-99) (accession 0001390478-25-000004): "-Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 -" https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm

### 2025: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2025-03-20, last confirmed 2025-05-13.
- Press release filed with the SEC (EX-99) (accession 0001390478-25-000004): ""The most anticipated milestones in 2025 will be the final analysis of our Phase 3 pivotal REGAL trial of GPS in acute myeloid leukemia (AML) and the full topline Phase 2 data of SLS009 in AML, both of which represent significant opportunities and offer hope to AML patients in need." https://www.sec.gov/Archives/edgar/data/1390478/000139047825000004/sls-202503208xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-25-000009): "With the full topline Phase 2 data of SLS009 anticipated soon, and the final analysis of our Phase 3 pivotal REGAL trial of GPS in AML expected later this year, we are well-positioned for an exciting and meaningful 2025."" https://www.sec.gov/Archives/edgar/data/1390478/000139047825000009/sls-202505138xkexhibit991.htm

### Q4 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-12, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000021): "- 40 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Preliminary Topline Data Expected in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-202611128xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000021): "Preliminary topline data is expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1390478/000139047826000021/sls-202611128xkexhibit991.htm

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-05-12, last confirmed 2026-08-11.
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000013): "- 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -" https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000013): "At the same time, we are making meaningful progress with SLS009 in our ongoing Phase 2 frontline AML study, where dosing continues and enrollment is tracking ahead of industry standards, with topline data expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000013): "Topline data expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1390478/000139047826000013/sls-202608118xkexhibit991.htm
- Press release filed with the SEC (EX-99) (accession 0001390478-26-000009): "The topline data are expected in Q4 2026." https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-202605128xkexhibit991.htm

## Same indication

- [Annamycin](https://sec-api.dev/pdufa/annamycin) (MBRX)
- [ONUREG (azacitidine)](https://sec-api.dev/pdufa/azacitidine) (BMY)
- [TSC-101](https://sec-api.dev/pdufa/tsc-101) (TCRX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tambiciclib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Tambiciclib PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tambiciclib

```bibtex
@misc{secapidev_pdufa_tambiciclib_20261116,
  title        = {Tambiciclib PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tambiciclib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tambiciclib_20261116","title":"Tambiciclib PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tambiciclib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
